Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Gastroparesis

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Persistent vomiting with dehydration, severe electrolyte disturbance, diabetic ketoacidosis, hypoglycaemia, haematemesis, faeculent vomit, sudden severe pain or suspected bezoar obstruction requires acute assessment. Check capillary glucose and ketones promptly in diabetes, give intravenous fluid and electrolyte replacement according to measured need, and exclude mechanical obstruction before any prokinetic. A distended food-filled stomach also creates substantial aspiration risk during sedation or anaesthesia, even after standard fasting.

Synopsis

Diagnose gastroparesis only after excluding mechanical obstruction, measure delayed gastric emptying with an appropriate test, restore nutrition and glycaemic stability, and use prokinetic or device treatment within current UK safety restrictions.

  • Gastroparesis is a symptom-compatible delay in gastric emptying without a mechanical blockage; symptoms alone and retained food at one endoscopy are insufficient for diagnosis.
  • Typical features are postprandial fullness, early satiety, nausea, vomiting, bloating and upper abdominal pain, but their severity correlates imperfectly with measured emptying delay.
  • Diabetes, vagal injury after upper-GI surgery, neurological or connective-tissue disease and medicines that slow motility are recognised causes; many cases remain idiopathic.
  • Review opioids, antimuscarinics and GLP-1 receptor agonists among other medicines, while avoiding abrupt withdrawal when the original indication or metabolic benefit is important.
  • Upper-GI endoscopy or anatomical imaging excludes obstruction; standardised solid-meal gastric-emptying scintigraphy is the conventional objective test for delayed emptying.
  • Dietetic treatment uses smaller, more frequent and easier-to-empty meals with texture, fat and fibre adapted to symptoms while protecting energy, protein and micronutrient intake.
  • Metoclopramide, domperidone and erythromycin all have major duration, licensing, neurological, cardiac or interaction limitations, so chronic repeat prescribing without specialist review is unsafe.
  • Severe refractory disease may require jejunal feeding, venting, pylorus-directed therapy or gastric electrical stimulation through a specialist motility and nutrition MDT.

Key red flags

Diabetic instability

Longstanding diabetes with autonomic neuropathy, unpredictable post-meal glucose and recurrent early hypoglycaemia may reflect a mismatch between insulin action and delayed carbohydrate delivery. Check ketones during acute illness.

Bezoar or obstruction clue

A palpable succussion splash, focal transition on imaging, severe distension, faeculent vomiting or inability to tolerate liquids argues for mechanical obstruction or bezoar and prohibits reflex prokinetic treatment.

Investigation priorities

01
Upper-GI endoscopyFirst step

Exclude a mucosal, pyloric or duodenal mechanical cause and inspect retained contents.

Management branches

ConfirmSeparate delay from blockage

Chronic meal-related fullness, nausea or food vomiting raises suspicion of impaired gastric emptying.

  1. Take a detailed symptom, surgical, diabetes, eating-behaviour and medicine history, measure weight trajectory, hydration, glucose and electrolytes, and identify cancer or obstruction features.
  2. Exclude structural disease through endoscopy and appropriate imaging before arranging a standardised solid-meal gastric-emptying study under valid glucose and medicine conditions.
  3. Only apply the gastroparesis label when compatible symptoms, objective delay and absence of mechanical obstruction converge; reconsider functional dyspepsia or another vomiting disorder when they do not.

Key medicines

Metoclopramide for short-term nausea and vomitingThe adult licensed dose is 10 mg up to three times daily, maximum 30 mg or 0.5 mg/kg in 24 hours, for no longer than five days; gastroparesis use beyond the licence requires specialist governance.Avoid in mechanical obstruction, bleeding or perforation. Monitor acute dystonia, akathisia, parkinsonism, sedation and tardive dyskinesia risk; reduce for renal or hepatic impairment and avoid unsafe dopamine-active combinations.
Domperidone for short-term nausea and vomitingFor licensed adults and adolescents at least 12 years and 35 kg, use 10 mg up to three times daily, maximum 30 mg daily, usually for no longer than one week.Contraindicated when stimulation could harm, including obstruction, bleeding or perforation, and with QT prolongation, significant cardiac disease, severe hepatic impairment, potent CYP3A4 inhibitors, QT-prolonging drugs or confirmed or suspected phaeochromocytoma. Correct potassium and magnesium and review ECG need.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS gastroparesis clinical overviewCurrent UK symptom, diagnostic, dietary, medicine, nutrition and advanced-treatment overview, reviewed July 2026.
  • NICE HTG341: Gastric electrical stimulationUK interventional governance for specialist device treatment of gastroparesis.
  • NICE evidence summary: Oral erythromycin for gastroparesisEvidence and off-label limitations for erythromycin as an adult prokinetic.
  • MHRA metoclopramide neurological safety updateUK five-day duration, maximum adult dose and neurological-risk restrictions.
  • MHRA domperidone cardiac safety updateCurrent July 2026 contraindications plus reminder of dose, duration, QT and interaction restrictions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting review
JurisdictionUnited Kingdom